847728-90-9

Basic information

• Product Name: Benzoic acid, 4-[(1S)-1-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-, methyl ester
• CAS NO: 847728-90-9
• Molecular Formula: C15H21NO4
• Molecular Weight: 279.336
• Mol File: 847728-90-9.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-[(1S)-1-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-[(1S)-1-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-, methyl ester(847728-90-9)
• EPA Substance Registry System: Benzoic acid, 4-[(1S)-1-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-, methyl ester(847728-90-9)

Safety Data

• Hazardous Substances Data: 847728-90-9(Hazardous Substances Data)

Usage

General Description

Benzoic acid, 4-[(1S)-1-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-, methyl ester is a chemical compound that is used in various industrial and pharmaceutical applications. It is a methyl ester of benzoic acid and it contains an aminoethyl group. It is often used as a pharmaceutical intermediate for the synthesis of various drugs and active pharmaceutical ingredients. Additionally, it can also be utilized as a chemical intermediate in the production of various flavors and fragrances. Benzoic acid, 4-[(1S)-1-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-, methyl ester is known for its ability to modify the properties of other chemicals and enhance their stability and shelf life.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 84499-77-4 (S)-α-(p-bromophenyl)ethylamine hydrochloride 
• 847728-89-6 (S)-tert-butyl (1-(4-bromophenyl)ethyl)carbamate 
• 124-38-9 carbon dioxide 
• 917-54-4 methyllithium 
• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 

Downstream Products

• 222714-37-6 4-[(1S)-1-aminoethyl]-benzoic acid, methyl ester 
• 868637-14-3 methyl 4-{(1S)-1-[({5-chloro-2-[methyl(2-phenylethyl)amino]pyridin-3-yl}carbonyl)amino]ethyl}benzoate 
• 868636-95-7 Methyl 4-[(1S)-1-[(5-chloro-2-hydroxybenzoyl)amino]ethyl}benzoate 
• 847729-10-6 methyl 4-[(1S)-1-[(2,5-dichloropyridin-3-yl)formamido]ethyl]benzoate 
• 1429176-51-1 (S)-4-isopropyl-3-(2-(((S)-1-(4-(piperazin-1-ylmethyl)phenyl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one 
• 1429176-78-2 benzyl 4-(4-((S)-1-((4-((S)-4-isopropyl-2-oxooxazolidin-3-yl)pyrimidin-2-yl)amino)ethyl)benzyl)piperazine-1-carboxylate 
• 1429181-46-3 benzyl (S)-4-(4-(1-aminoethyl)benzyl)piperazine-1-carboxylate 
• 1429181-45-2 benzyl (S)-4-(4-(1-((tert-butoxycarbonyl)amino)ethyl)benzyl)piperazine-1-carboxylate 
• 1429181-29-2 (S)-1-(4-((5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methyl)phenyl)thanamine 
• 1429181-28-1 (S)-tert-butyl 1-(4-((5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methyl)phenyl)ethylcarbamate 
• 1429181-27-0 tert-butyl (S)-(1-(4-(chloromethyl)phenyl)ethyl)carbamate 
• 1380754-50-6 (S)-methyl 4-(1-(5-chloro-2-(3-(4-fluorophenoxy)azetidin-1-yl)nicotinamido)ethyl)benzoate 

Relevant articles and documents

Discovery and characterization of a potent and selective EP4 receptor antagonist

Abstract EP4 is a prostaglandin E2 receptor that is a target for potential anti-nociceptive therapy. Described herein is a class of amphoteric EP4 antagonists which reverses PGE2-induced suppression of TNFα prod

PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

The invention relates pyridine amide derivative of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently hydrogen, linear o branched (C1-C3)alkyl or joined together they form a cyclopropyl ring; R is independently selected from the group consisting of halogens and trifluoromethyl and p is 1, 2 or 3; A is C or N; E is a group of formula (B) or (C), wherein B is C(O)OH, C(O)O(C1-C3)alkyl, and C is selected from the group consisting of formula (I) m is 1,2 or 3, n is 0 or 1, W is —O—, —O(C1-C3 alkyl)-; —(C1-C3 alkyl)O—; —C(O)—; —C(═N—O(C1-C3 alkyl))-; —NH— or —NH(C1-C3alkyl)-; Ar is phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, methyl, —NH(C1-C3alkyl)-; —N(C1-C3alkyl)(C1-C3alkyl)-, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom which is covalently bonded to Ar and optionally containing one or two heteroatoms selected from N, O and S; and a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O e N, such heteroaromatic ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl. The compounds of the invention could be used for manufacturing a medicament for the treatment of pathologies which require the use of an antagonist of the EP4 receptor, such as the treatment of acute and chronic pain, inflammatory pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, endometriosis and migraine.

A novel series of potent and selective EP4 receptor ligands: Facile modulation of agonism and antagonism

A novel series of EP4 ligands, based on a benzyl indoline scaffold, has been discovered. It was found that agonism and antagonism in this series can be easily modulated by minor modifications on the benzyl group. The pharmacokinetic, metabolic